These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 37863324)
1. E2F8 exerts cancer-promoting effects by transcriptionally activating RRM2 and E2F8 knockdown synergizes with WEE1 inhibition in suppressing lung adenocarcinoma. Liu K; Wang L; Lou Z; Guo L; Xu Y; Qi H; Fang Z; Mei L; Chen X; Zhang X; Shao J; Xiang X Biochem Pharmacol; 2023 Dec; 218():115854. PubMed ID: 37863324 [TBL] [Abstract][Full Text] [Related]
2. A MYBL2 complex for RRM2 transactivation and the synthetic effect of MYBL2 knockdown with WEE1 inhibition against colorectal cancer. Liu Q; Guo L; Qi H; Lou M; Wang R; Hai B; Xu K; Zhu L; Ding Y; Li C; Xie L; Shen J; Xiang X; Shao J Cell Death Dis; 2021 Jul; 12(7):683. PubMed ID: 34234118 [TBL] [Abstract][Full Text] [Related]
3. MicroRNA-1-3p affects lung adenocarcinoma progression through E2F8 and regulating NF-кB pathway. Lin Q Cytokine; 2022 Aug; 156():155922. PubMed ID: 35660716 [TBL] [Abstract][Full Text] [Related]
4. High expression of RRM2 as an independent predictive factor of poor prognosis in patients with lung adenocarcinoma. Jin CY; Du L; Nuerlan AH; Wang XL; Yang YW; Guo R Aging (Albany NY); 2020 Dec; 13(3):3518-3535. PubMed ID: 33411689 [TBL] [Abstract][Full Text] [Related]
5. CA916798 predicts poor prognosis and promotes Gefitinib resistance for lung adenocarcinoma. He J; Lan X; Liu X; Deng C; Luo H; Wang Y; Kang P; Sun Z; Zhao L; Zhou X BMC Cancer; 2023 Mar; 23(1):266. PubMed ID: 36959566 [TBL] [Abstract][Full Text] [Related]
6. RRM2 silencing suppresses malignant phenotype and enhances radiosensitivity via activating cGAS/STING signaling pathway in lung adenocarcinoma. Jiang X; Li Y; Zhang N; Gao Y; Han L; Li S; Li J; Liu X; Gong Y; Xie C Cell Biosci; 2021 Apr; 11(1):74. PubMed ID: 33858512 [TBL] [Abstract][Full Text] [Related]
7. MiR-202-3p inhibits the proliferation and metastasis of lung adenocarcinoma cells by targeting RRM2. Cao X; Xue F; Chen H; Shen L; Yuan X; Yu Y; Zong Y; Zhong L; Huang F Ann Transl Med; 2022 Dec; 10(24):1374. PubMed ID: 36660663 [TBL] [Abstract][Full Text] [Related]
8. Downregulation of Linc00173 increases BCL2 mRNA stability via the miR-1275/PROCA1/ZFP36L2 axis and induces acquired cisplatin resistance of lung adenocarcinoma. Tao X; Li Y; Fan S; Wu L; Xin J; Su Y; Xian X; Huang Y; Huang R; Fang W; Liu Z J Exp Clin Cancer Res; 2023 Jan; 42(1):12. PubMed ID: 36627670 [TBL] [Abstract][Full Text] [Related]
9. APE1 stimulates EGFR-TKI resistance by activating Akt signaling through a redox-dependent mechanism in lung adenocarcinoma. Lu GS; Li M; Xu CX; Wang D Cell Death Dis; 2018 Oct; 9(11):1111. PubMed ID: 30382076 [TBL] [Abstract][Full Text] [Related]
10. [miR-218-5p Targeting TPX2 Regulates p53 Pathway and Inhibits Malignant Progression of Lung Adenocarcinoma]. Xu J Zhongguo Fei Ai Za Zhi; 2023 Oct; 26(10):721-731. PubMed ID: 37989335 [TBL] [Abstract][Full Text] [Related]
11. Transcription Factor E2F8 Activates PDK1-Mediated DNA Damage Repair to Enhance Cisplatin Resistance in Lung Adenocarcinoma. Li H; Sun J; Hu H; Wang Y Pharmacology; 2024 May; 109(6):341-356. PubMed ID: 38810606 [TBL] [Abstract][Full Text] [Related]
12. Protumor Effects of Histone H3-H4 Chaperone Antisilencing Feature 1B Gene on Lung Adenocarcinoma: In Silico and Wu L; Jie B Comput Math Methods Med; 2021; 2021():5005459. PubMed ID: 34956399 [TBL] [Abstract][Full Text] [Related]
13. Overexpression of BCCIP predicts an unfavorable prognosis and promotes the proliferation and migration of lung adenocarcinoma. Shi J; Lv X; Li W; Ming Z; Zeng L; Yuan J; Chen Y; Liu B; Yang S Thorac Cancer; 2021 Sep; 12(17):2324-2338. PubMed ID: 34297484 [TBL] [Abstract][Full Text] [Related]
14. Rucaparib inhibits lung adenocarcinoma cell proliferation and migration via the SHCBP1/CDK1 pathway. Dai Y; Hu C; Zhou H; Liu W; Lai W; Xu R; Liao J; Wang J; Li G; Zhang R FEBS J; 2023 Dec; 290(24):5720-5743. PubMed ID: 37581853 [TBL] [Abstract][Full Text] [Related]
15. Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation. Pfister SX; Markkanen E; Jiang Y; Sarkar S; Woodcock M; Orlando G; Mavrommati I; Pai CC; Zalmas LP; Drobnitzky N; Dianov GL; Verrill C; Macaulay VM; Ying S; La Thangue NB; D'Angiolella V; Ryan AJ; Humphrey TC Cancer Cell; 2015 Nov; 28(5):557-568. PubMed ID: 26602815 [TBL] [Abstract][Full Text] [Related]
16. Knockdown of replication protein A 3 induces protective autophagy and enhances cisplatin sensitivity in lung adenocarcinoma by inhibiting AKT/mTOR signaling via binding to cyclin-dependent kinases regulatory subunit 2. Chen L; Hu K; Liu Y; Liu L; Tang J; Qin X Drug Dev Res; 2022 Nov; 83(7):1589-1599. PubMed ID: 35903032 [TBL] [Abstract][Full Text] [Related]
17. ETV4 promotes proliferation and invasion of lung adenocarcinoma by transcriptionally upregulating MSI2. Cheng T; Zhang Z; Cheng Y; Zhang J; Tang J; Tan Z; Liang Z; Chen T; Liu Z; Li J; Zhao J; Zhou R Biochem Biophys Res Commun; 2019 Aug; 516(1):278-284. PubMed ID: 31253395 [TBL] [Abstract][Full Text] [Related]
18. PKMYT1 inhibits lung adenocarcinoma progression by abrogating AKT1 activity. Wang S; Liu X; Zhou T; Li J; Lin Y; Zhou A; Huang J; Zhao J; Cai J; Cai X; Huang Y; Li X Cell Oncol (Dordr); 2023 Feb; 46(1):195-209. PubMed ID: 36350496 [TBL] [Abstract][Full Text] [Related]
19. Identification of critical ferroptosis regulators in lung adenocarcinoma that RRM2 facilitates tumor immune infiltration by inhibiting ferroptotic death. Tang B; Xu W; Wang Y; Zhu J; Wang H; Tu J; Weng Q; Kong C; Yang Y; Qiu R; Zhao Z; Xu M; Ji J Clin Immunol; 2021 Nov; 232():108872. PubMed ID: 34648954 [TBL] [Abstract][Full Text] [Related]
20. CAPN1 promotes malignant behavior and erlotinib resistance mediated by phosphorylation of c-Met and PIK3R2 via degrading PTPN1 in lung adenocarcinoma. Chen Y; Tang J; Lu T; Liu F Thorac Cancer; 2020 Jul; 11(7):1848-1860. PubMed ID: 32395869 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]